Nephrocalcinosis and urolithiasis in children

Kidney International

Volumn 80, Issue 12, 2011, Pages 1278-1291

  Habbig, Sandra ^a   Beck, Bodo Bernhard ^a,b   Hoppe, Bernd ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

childhood; hypercalciuria; hyperoxalauria; hypocitraturia; nephrocalcinosis; urolithiasis

Indexed keywords

4 METHYLPYRAZOLE; ACICLOVIR; ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMOXICILLIN; AMPICILLIN; ASCORBIC ACID; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CEFTRIAXONE; CORTICOSTEROID; HYDROCHLOROTHIAZIDE; INDINAVIR; OXALIC ACID; PENICILLAMINE; PYRIDOXAL 5 PHOSPHATE; SULFONAMIDE; THIAZIDE DIURETIC AGENT; TIOPRONIN; TRIAMTERENE;

ABNORMAL URINE COMPOSITION; ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; BODY MASS; BONE DEMINERALIZATION; CELL PROLIFERATION; CHILD HEALTH; COMPUTER ASSISTED TOMOGRAPHY; CRYSTALLIZATION; CYSTINURIA; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG ERUPTION; ECHOGRAPHY; ENDOSCOPY; ENVIRONMENTAL FACTOR; FLUID INTAKE; FOOD INTAKE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; GROWTH RETARDATION; HEMODIALYSIS; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; HYPERURICOSURIA; HYPOCITRATURIA; HYPOKALEMIA; HYPOTENSION; INCIDENCE; KIDNEY CALCIFICATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; METABOLIC ACIDOSIS; NEPHRITIS; OXALOSIS 1; PATHOGENESIS; POLYMYOSITIS; POLYNEUROPATHY; PREVALENCE; PRIMARY HYPEROXALURIA TYPE II; PRIORITY JOURNAL; RACE DIFFERENCE; RASH; RISK FACTOR; SECONDARY ENTERIC HYPEROXALURIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; URINARY TRACT INFECTION; UROLITHIASIS; VESICULAR RASH; WAIST CIRCUMFERENCE;

EID: 82455175289     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.336     Document Type: Review

References (186)

1. VanDervoort K, Wiesen J, Frank R et al. Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 2007; 177: 2300-2305.
2. Sas DJ, Hulsey TC, Shatat IF et al. Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr 2010; 157: 132-137.
3. Hoppe B, Leumann A, Milliner DS. Urolithiasis and nephrocalcinosis in childhood. In: Geary DF, Schaefer F (eds). Comprehensive Pediatric Nephrology. Elsevier: Philadelphia, 2008, pp 499-525.
4. Hoppe B, Kemper M. Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatr Nephrol 2010; 25: 403-413.
5. Dick PT, Shuckett BM, Tang B et al. Observer reliability in grading nephroc ultrasound examinations in children. Pediatr Radiol 1999; 29: 68-72.
6. Persaud AC, Stevenson MD, McMahon DR et al. Pediatric urolithiasis: clinical predictors in the emergency department. Pediatrics 2009; 124: 888-894.
7. Johnson CM, Wilson DM, O0Fallon WM et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 1979; 16: 624-631.
8. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005; 115: 2598-2608.
9. Walther PC, Lamm D, Kaplan GW. Pediatric urolithiases: a ten-year review. Pediatrics 1980; 65: 1068-1072.
10. Milliner DS, Murphy ME. Urolithiasis in pediatric patients. Mayo Clin Proc 1993; 68: 241-248.
11. Alon US. Nephrocalcinosis. Curr Opin Pediatr 1997; 9: 160-165.
12. Pietrow PK, Pope JC, Adams MC et al. Clinical outcome of pediatric stone disease. J Urol 2002; 167: 670-673.
13. Kalorin CM, Zabinski A, Okpareke I et al. Pediatric urinary stone disease- does age matter? J Urol 2009; 181: 2267-2271.
14. Cameron MA, Sakhaee K, Moe OW. Nephrolithiasis in children. Pediatr Nephrol 2005; 20: 1587-1592.
15. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293: 455-462.
16. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
17. West B, Luke A, Durazo-Arvizu RA, Cao G et al. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis 2008; 51: 741-747.
18. Duffey BG, Pedro RN, Kriedberg C et al. Lithogenic risk factors in the morbidly obese population. J Urol 2008; 179: 1401-1406.
19. Novak TE, Lakshmanan Y, Trock BJ et al. Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation. Urology 2009; 74: 104-107.
20. Kit LC, Filler G, Pike J et al. Pediatric urolithiasis: experience at a tertiary care pediatric hospital. Can Urol Assoc J 2008; 2: 381-386.
21. Perrone HC, dos Santos DR, Santos MV et al. Urolithiasis in childhood: metabolic evaluation. Pedr Nephrol 1992; 6: 54-56.
22. van0t Hoff WG. Aetiological factors in paediatric urolithiasis. Nephron Clin Pract 2004; 98: c45-c48.
23. Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. Clin Sci (Lond) 2004; 106: 549-561.
24. Evan AP, Lingeman J, Coe F et al. Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 2007; 71: 795-801.
25. Polito C, Iolascon G, Nappi B et al. Growth and bone mineral density in long-lasting idiopathic hypercalciuria. Pediatr Nephrol 2003; 18: 545-547.
26. Miller NL, Humphreys MR, Coe FL et al. Nephrocalcinosis: re-defined in the era of endourology. Urol Res 2010; 38: 421-427.
27. Le JD, Eisner BH, Tseng TY et al. Laterality of nephrocalcinosis in kidney stone formers with severe hypocitraturia. BJU Int 2011; 107: 106-110.
28. Pope IV JC, Trusler LA, Klein AM et al. The natural history of nephrocalcinosis in premature infants treated with loop diuretics. J Urol 1996; 156: 709-712.
29. Auron A, Alon US. Resolution of medullary nephrocalcinosis in children with metabolic bone disorders. Pediatr Nephrol 2005; 20: 1143-1145.
30. Goldfarb DS. Increasing prevalence of kidney stones in the United States. Kidney Int 2003; 63: 1951-1952.
31. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15: 3225-3232.
32. López M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol 2008; 25: 49-59.
33. Randall A. The origin and growth of renal calculi. Ann Surg 1937; 105: 1009-1027.
34. Coe FL, Evan AP, Worcester EM et al. Three pathways for human kidney stone formation. Urol Res 2010; 38: 147-160.
35. Vervaet BA, Verhulst A, D'Haese PC et al. Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol Dial Transplant 2009; 24: 2030-2035.
36. Asplin JR, Parks JH, Coe FL. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int 1997; 52: 1602-1608.
37. Ryall RL, Fleming DE, Grover PK et al. The hole truth: intracrystalline proteins and calcium oxalate kidney stones. Mol Urol 2000; 4: 391-402.
38. Verhulst A, Asselman M, Persy VP et al. Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding- into a nonadherent epithelium. J Am Soc Nephrol 2003; 14: 107-115.
39. Asselman M, Verhulst A, De Broe ME et al. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003; 14: 3155-3166.
40. Verhulst A, Asselman M, De Naeyer S et al. Preconditioning of the distal tubular epithelium of the human kidney precedes nephrocalcinosis. Kidney Int 2005; 68: 1643-1647.
41. Verkoelen CF, Van Der Boom BG, Romijn JC. Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells. Kidney Int 2000; 58: 1045-1054.
42. Spivacow FR, Negri AL, del Valle EE et al. Clinical and metabolic risk factor evaluation in young adults with kidney stones. Int Urol Nephrol 2010; 42: 471-475.
43. Ammenti A, Neri E, Agistri R et al. Idiopathic hypercalciuria in infants with renal stones. Pediatr Nephrol 2006; 21: 1901-1903.
44. Rönnefarth G, Misselwitz J. Nephrocalcinosis in children: a retrospective survey. Members of the Arbeitsgemeinschaft für pädiatrische Nephrologie. Pediatr Nephrol 2000; 14: 1016-1021.
45. Ghazali S, Barratt TM. Urinary excretion of calcium and magnesium in children. Arch Dis Child 1974; 49: 97-101.
46. De Santo NG, Di Iorio B, Capasso G et al. Population based data on urinary excretion of calcium, magnesium, oxalate, phosphate and uric acid in children from Cimitile (southern Italy). Pediatr Nephrol 1992; 6: 149-157.
47. Moxey-Mims MM, Stapleton FB. Hypercalciuria and nephrocalcinosis in children. Curr Opin Pediatr 1993; 5: 186-190.
48. Gambaro G, Vezzoli G, Casari G et al. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004; 44: 963-986.
49. Vezzoli G, Terranegra A, Arcidiacono T et al. Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region. Nephrol Dial Transplant 2010; 25: 2245-2252.
50. Pearce SH, Williamson C, Kifor O et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calciumsensing receptor. N Engl J Med 1996; 335: 1115-1122.
51. Petrucci M, Scott P, Ouimet D et al. Evaluation of the calcium-sensing receptor gene in idiopathic hypercalciuria and calcium nephrolithiasis. Kidney Int 2000; 58: 38-42.
52. Vezzoli G, Tanini A, Ferrucci L et al. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol 2002; 13: 2517-2523.
53. Lloyd SE, Pearce SH, Fisher SE et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996; 379: 445-449.
54. Buckalew VM. Nephrolithiasis in renal tubular acidosis. J Urol 1989; 141: 731-737.
55. Hamm LL. Renal handling of citrate. Kidney Int 1990; 38: 728-735.
56. Breslau NA. Pathogenesis and management of hypercalciuric nephrolithiasis. Miner Electrolyte Metab 1994; 20: 328-339.
57. Damiani D, Aguiar CH, Bueno VS et al. Primary hyperparathyroidism in children: patient report and review of the literature. J Pediatr Endocrinol Metab 1998; 11: 83-86.
58. Ragavan VV, Smith JE, Bilezikian JP. Vitamin A toxicity and hypercalcemia. Am J Med Sci 1982; 283: 161-164.
59. Bhalla K, Ennis DM, Ennis ED. Hypercalcemia caused by iatrogenic hypervitaminosis A. J Am Diet Assoc 2005; 105: 119-121.
60. Zanchetta JR, Rodriguez G, Negri AL et al. Bone mineral density in patients with hypercalciuric nephrolithiasis. Nephron 1996; 73: 557-560.
61. Kamitsuka MD, Williams MA, Nyberg DA et al. Renal calcification: a complication of dexamethasone therapy in preterm infants with bronchopulmonary dysplasia. J Perinatol 1995; 15: 359-363.
62. Rausch HP, Hanefeld F, Kaufmann HJ. Medullary nephrocalcinosis and pancreatic calcifications demonstrated by ultrasound and CT in infants after treatment with ACTH. Radiology 1984; 153: 105-107.
63. Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr 1994; 125: 149-151.
64. Hufnagle KG, Khan SN, Penn D et al. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 1982; 70: 360-363.
65. Gückel C, Benz-Bohm G, Roth B. Nephrocalcinosis in childhood. Sonographic findings and differential diagnosis. Rofo 1989; 151: 301-305.
66. Cote G, Jequier S, Kaplan P. Increased renal medullary echogenicity in patients with Williams syndrome. Pediatr Radiol 1989; 19: 481-483.
67. Hoppe B, Neuhaus T, Superti-Furga A et al. Hypercalciuria and nephrocalcinosis, a feature of Wilson's disease. Nephron 1993; 65: 460-462.
68. Sliman GA, Winters WD, Shaw DW et al. Hypercalciuria and nephrocalcinosis in the oculocerebrorenal syndrome. J Urol 1995; 153: 1244-1246.
69. Laufer J, Boichis H. Urolithiasis in children: current medical management. Pediatr Nephrol 1989; 3: 317-331.
70. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327: 1141-1152.
71. Campfield T, Braden G. Urinary oxalate excretion by very low birth weight infants receiving parenteral nutrition. Pediatrics 1989; 84: 860-863.
72. Hoppe B, Hesse A, Neuhaus T et al. Urinary saturation and nephrocalcinosis in preterm infants: effect of parenteral nutrition. Arch Dis Child 1993; 69: 299-303.
73. Williams HE, Wandzilak TR. Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 1989; 141: 742-749.
74. Monico CG, Milliner DS. Hyperoxaluria and urolithiasis in young children: an atypical presentation. J Endourol 1999; 13: 633-636.
75. Danpure CJ. Recent advances in the understanding, diagnosis and treatment of primary hyperoxaluria type 1. J Inherit Metab Dis 1989; 12: 210-224.
76. Purdue PE, Lumb MJ, Fox M et al. Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 1991; 10: 34-42.
77. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int 2009; 75: 1264-1271.
78. Akhan O, Ozmen MN, deg;kun M et al. Systemic oxalosis: pathognomonic renal and specific extrarenal findings on US and CT. Pediatr Radiol 1995; 25: 15-16.
79. Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Nephrol 2001; 12: 1986-1993.
80. Hoppe B, Langman CB. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 2003; 18: 986-991.
81. Cregeen DP, Williams EL, Hulton S, Rumsby G. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat 2003; 22: 497.
82. Cregeen DP, Rumsby G. Recent developments in our understanding of primary hyperoxaluria type 2. J Am Soc Nephrol 1999; 10: S348-S350.
83. Marangella M, Petrarulo M, Cosseddu D. End-stage renal failure in primary hyperoxaluria type 2. N Engl J Med 1999; 330: 1690.
84. Monico CG, Rossetti S, Belostotsky R et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 2011; 6: 2289-2295.
85. Blostosky R, Seboun E, Idelson GH et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 2010; 87: 392-399.
86. Sidhu H, Hoppe B, Hesse A et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998; 352: 1026-1029.
87. Hoppe B, Roth B, Bauerfeld C et al. Oxalate, citrate, and sulfate concentration in human milk compared with formula preparations: influence on urinary anion excretion. J Pediatr Gastroenterol Nutr 1998; 27: 383-386.
88. Hoppe B, von Unruh GE, Blank G et al. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis 2005; 46: 440-445.
89. Neuhaus TJ, Belzer T, Blau N et al. Urinary oxalate excretion in urolithiasis and nephrocalcinosis. Arch Dis Child 2000; 82: 322-326.
90. Beck B, Habbig S, Feldkötter M et al. How to handle the dilemma of ESRF and systemic oxalosis in short bowel syndrome from Crohn's disease - a potential application for Oxalobacter formigenes. Pediatr Nephrol 2008; 23: 1613.
91. Miller LA, Stapleton FB. Urinary citrate excretion in children with hypercalciuria. J Pediatr 1985; 107: 263-266.
92. Preminger GM, Sakhaee K, Skurla C et al. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985; 134: 20-23.
93. Daudon M, Estepa L. [Drug induced lithiases]. Presse Med 1998; 27: 675-683.
94. Hylander B, Kjellstrand CM. Prognostic factors and treatment of severe ethylene glycol intoxication. Int Care Med 1996; 22: 546-552.
95. Howard SC, Kaplan SD, Razzouk BI et al. Urolithiasis in pediatric patients with acute lymphoblastic leukemia. Leukemia 2003; 17: 541-546.
96. Kaste SC, Thomas NA, Rai SN et al. Asymptomatic kidney stones in longterm survivors of childhood acute lymphoblastic leukemia. Leukemia 2009; 23: 104-108.
97. LaRosa C, McMullen L, Bakdash S et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007; 22: 132-135.
98. Cabello-Tomás ML, Garc?́a-Gómez AM, Guillén-Dom?́nguez ML. Pilot screening programme for cystinuria in the Valencian community. Eur J Epidemiol 1999; 15: 681-684.
99. Schön R, Thalhammer O. [Routine screening for inborn errors using urine filterpaper specimens at age 4-5 weeks (author's transl)]. Padiatr Padol 1976; 11: 319-325.
100. Erbagci A, Erbagci AB, Yilmaz M et al. Pediatric urolithiasis-evaluation of risk factors in 95 children. Scand. J Urol Nephrol 2003; 37: 129-133.
101. Faerber GJ. Pediatric urolithiasis. Curr Opin Urol 2001; 11: 385-389.
102. Coward RJM, Peters CJ, Duffy PG et al. Epidemiology of paediatric renal stone disease in the UK. Arch Dis Child 2003; 88: 962-965.
103. Knoll T, Zöllner A, Wendt-Nordahl G et al. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 2005; 20: 19-24.
104. Dello Strologo L, Pras E, Pontesilli C et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol 2002; 13: 2547-2553.
105. Dent CE, Senior B. Studies on the treatment of cystinuria. Br J Urol 1955; 27: 317-332.
106. Cameron JS, Moro F, Simmonds HA. Gout, uric acid and purine metabolism in paediatric nephrology. Pediatr Nephrol 1993; 7: 105-118.
107. Choi Y, Koo JW, Ha IS et al. Partial hypoxanthine-guanine phosphoribosyl transferase deficiency in two Korean siblings-a new mutation. Pediatr Nephrol 1993; 7: 739-740.
108. Restaino I, Kaplan BS, Stanley C et al. Nephrolithiasis, hypocitraturia, and a distal renal tubular acidification defect in type 1 glycogen storage disease. J Pediatr 1993; 122: 392-396.
109. Ceballos-Picot I, Perignon JL, Hamet M et al. 2,8-Dihydroxyadenine urolithiasis, an underdiagnosed disease. Lancet 1992; 339: 1050-1051.
110. Arikyants N, Sarkissia A, Hesse A et al. Xanthinuria type I: a rare cause of urolithiasis. Pediatr Nephrol 2007; 22: 310-314.
111. Brueziere J, Roubach L. Urinary lithiasis in children. Eur Urol 1981; 7: 134-135.
112. Raj GV, Bennett RT, Preminger GM et al. The incidence of nephrolithiasis in patients with spinal neural tube defects. J Urol 1999; 162: 1238-1242.
113. Oǧuzkurt L, Karabulut N, Haliloǧlu M et al. Medullary nephrocalcinosis associated with vesicoureteral reflux. Br J Radiol 1997; 70: 850-851.
114. Guan N, Fan Q, Ding J et al. Melamine-contaminated powdered formula and urolithiasis in young children. N Engl J Med 2009; 360: 1067-1074.
115. Bhalla V, Grimm PC, Chertow GM et al. Melamine nephrotoxicity: an emerging epidemic in an era of globalization. Kidney Int 2009; 75: 774-779.
116. Thompson ME, Lewin-Smith MR, Kalasinsky VF et al. Characterization of melamine-containing and calcium oxalate crystals in three dogs with suspected pet food-induced nephrotoxicosis. Vet Pathol 2008; 45: 417-426.
117. Puschner B, Poppenga RH, Lowenstine LJ et al. Assessment of melamine and cyanuric acid toxicity in cats. J Vet Diagn Invest 2007; 19: 616-624.
118. Brown CA, Jeong K, Poppenga RH et al. Outbreaks of renal failure associated with melamine and cyanuric acid in dogs and cats in 2004 and 2007. J Vet Diagn Invest 2007; 19: 525-531.
119. Collin F, Chêne G, Retout S et al. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. Ther Drug Monit 2007; 29: 164-170.
120. Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr Drug Saf 2007; 2: 147-154.
121. Brandenburg JJI, Hoepelman IM, Stapper G et al. [Three patients with indinavir-related urolithiasis]. Ned Tijdschr Geneeskd 2007; 151: 1839-1845.
122. + patients receiving Indinavir]. Arch Esp Urol 2008; 61: 35-40.
123. Heyns CF, Groeneveld AE, Sigarroa NB. Urologic complications of HIV and AIDS. Nat Clin Pract Urol 2009; 6: 32-43.
124. Kalaitzis C, Passadakis P, Giannakopoulos S et al. Urological management of indinavir-associated acute renal failure in HIV-positive patients. Int Urol Nephrol 2007; 39: 743-746.
125. Schell-Feith E, Kist-van Holthe J, van der Heijden A. Nephrocalcinosis in preterm neonates. Pediatr Nephrol 2010; 25: 221-230.
126. Schell-Feith EA, Holscher HC, Zonderland HM et al. Ultrasonographic features of nephrocalcinosis in preterm neonates. Br J Radiol 2000; 73: 1185-1191.
127. Hoppe B, Duran I, Martin A et al. Nephrocalcinosis in preterm infants: a single center experience. Pediatr Nephrol 2002; 17: 264-268.
128. Jacinto JS, Modanlou HD, Crade M et al. Renal calcification incidence in very low birth weight infants. Pediatrics 1988; 81: 31-35.
129. Short A, Cooke RW. The incidence of renal calcification in preterm infants. Arch Dis Child 1991; 66: 412-417.
130. Sheu JN, Chen CH, Lue KH et al. Renal calcification in very low birth weight infants. Am J Nephrol 1993; 13: 6-11.
131. Saarela T, Vaarala A, Lanning P et al. Incidence, ultrasonic patterns and resolution of nephrocalcinosis in very low birthweight infants. Acta Paediatr 1999; 88: 655-660.
132. Karlowicz MG, Katz ME, Adelman RD et al. Nephrocalcinosis in very low birth weight neonates: family history of kidney stones and ethnicity as independent risk factors. J Pediatr 1993; 122: 635-638.
133. Narendra A, White MP, Rolton HA et al. Nephrocalcinosis in preterm babies. Arch Dis Child Fetal Neonatal Ed 2001; 85: 207-213.
134. Hein G, Richter D, Manz F et al. Development of nephrocalcinosis in very low birth weight infants. Pediatr Nephrol 2004; 19: 616-620.
135. Ketkeaw K, Thaithumyanon P, Punnahitananda S. Nephrocalcinosis in very low birth weight infants: a single center experience. J Med Assoc Thai 2004; 87(S2): S72-S77.
136. Gimpel C, Krause A, Franck P et al. Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants. Pediatr Int 2010; 52: 51-56.
137. Schell-Feith EA, Kist-van Holthe JE, Conneman N et al. Etiology of nephrocalcinosis in preterm neonates: association of nutritional intake and urinary parameters. Kidney Int 2000; 58: 2102-2110.
138. Mirochnick MH, Miceli JJ, Kramer PA et al. Furosemide pharmacokinetics in very low birth weight infants. J Pediatr 1988; 112: 653-657.
139. Peterson RG, Simmons MA, Rumack BH et al. Pharmacology of furosemide in the premature newborn infant. J Pediatr 1980; 97: 139-143.
140. Cranefield DJ, Odd DE, Harding JE et al. High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone. Pediatr Radiol 2004; 34: 138-142.
141. Sikora P, Roth B, Kribs A et al. Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. Kidney Int 2003; 63: 2194-2199.
142. Jones CA, King S, Shaw NJ et al. Renal calcification in preterm infants: follow up at 4-5 years. Arch Dis Child Fetal Neonatal Ed 1997; 76: 185-189.
143. Kist-van Holthe JE, van Zwieten PHT, Schell-Feith EA et al. Is nephrocalcinosis in preterm neonates harmful for long-term blood pressure and renal function? Pediatrics 2007; 119: 468-475.
144. Porter E, McKie A, Beattie TJ et al. Neonatal nephrocalcinosis: long term follow up. Arch Dis Child Fetal Neonatal Ed 2006; 91: 333-336.
145. Schell-Feith EA, Kist-van Holthe JE, van Zwieten PHT et al. Preterm neonates with nephrocalcinosis: natural course and renal function. Pediatr Nephrol 2003; 18: 1102-1108.
146. Saarela T, Lanning P, Koivisto M. Prematurity-associated nephrocalcinosis and kidney function in early childhood. Pediatr Nephrol 1999; 13: 886-890.
147. Kistner A, Celsi G, Vanpee M et al. Increased blood pressure but normal renal function in adult women born preterm. Pediatr Nephrol 2000; 15: 215-220.
148. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
149. Stapenhorst L, Sassen R, Beck B et al. Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation. Pediatr Nephrol 2005; 20: 652-656.
150. Habbig S, Beck BB, Feldkötter M et al. Renal allograft calcification- prevalence and etiology in pediatric patients. Am J Nephrol 2009; 30: 194-200.
151. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5: 1934-1941.
152. Boom H, Mallat MJK, de Fijter JW et al. Calcium levels as a risk factor for delayed graft function. Transplantation 2004; 77: 868-873.
153. Pinheiro HS, Câmara NOS, Osaki KS et al. Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor longterm graft survival. Am J Transplant 2005; 5: 323-329.
154. Stapleton FB. Clinical approach to children with urolithiasis. Semin Nephrol 1996; 16: 389-397.
155. Sternberg K, Greenfield SP, Williot P et al. Pediatric stone disease: an evolving experience. J Urol 2005; 174: 1711-1714.
156. Oner S, Oto A, Tekgul S et al. Comparison of spiral CT and US in the evaluation of pediatric urolithiasis. JBR-BTR 2004; 87: 219-223.
157. Palmer JS, Donaher ER, O'Riordan MA et al. Diagnosis of pediatric urolithiasis: role of ultrasound and computerized tomography. J Urol 2005; 174: 1413-1416.
158. Strouse PJ, Bates DG, Bloom DA et al. Non-contrast thin-section helical CT of urinary tract calculi in children. Pediatr Radiol 2002; 32: 326-332.
159. Hollingsworth JM, Rogers MAM, Kaufman SR et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006; 368: 1171-1179.
160. Seitz C, Liatsikos E, Porpiglia F et al. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol 2009; 56: 455-471.
161. Alon US, Zimmerman H, Alon M. Evaluation and treatment of pediatric idiopathic urolithiasis-revisited. Pediatr Nephrol 2004; 19: 516-520.
162. Leumann E, Hoppe B, Neuhaus T. Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 1993; 7: 207-211.
163. Leumann E, Hoppe B, Neuhaus T et al. Efficacy of oral citrate administration in primary hyperoxaluria. Nephrol Dial Transplant 1995; 19: 14-16.
164. Blanchard A, Vargas-Poussou R, Peyrard S et al. Effect of hydrochlorothiazide on urinary calcium excretion in dent disease: an uncontrolled trial. Am J Kidney Dis 2008; 52: 1084-1095.
165. Hoppe B, Beck B, Gatter N et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006; 70: 1305-1311.
166. Hoppe B, Groothoff JW, Hulton SA et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 2011 (e-pub ahead of print, 2 April 2011).
167. Lux B, May P. Long-term observation of young cystinuric patients under ascorbic acid therapy. Urol Int 1983; 38: 91-94.
168. Birwé H, Schneeberger W, Hesse A. Investigations of the efficacy of ascorbic acid therapy in cystinuria. Urol Res 1991; 19: 199-201.
169. Stechman MJ, Loh NY, Thakker RV. Genetic causes of hypercalciuric nephrolithiasis. Pediatr Nephrol 2009; 24: 2321-2332.
170. Geng W, Wang Z, Zhang J et al. Cloning and characterization of the human soluble adenylyl cyclase. Am J Physiol 2005; 288: 1305-1316.
171. Wolf MTF, Zalewski I, Martin FC et al. Mapping a new suggestive gene locus for autosomal dominant nephrolithiasis to chromosome 9q33.2-q34.2 by total genome search for linkage. Nephrol Dial Transplant 2005; 20: 909-914.
172. Scott P, Ouimet D, Valiquette L et al. Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 1999; 10: 1007-1013.
173. Hoopes RR, Shrimpton AE, Knohl SJ et al. Dent disease with mutations in OCRL1. Am J Hum Genet 2005; 76: 260-267.
174. Leahey AM, Charnas LR, Nussbaum RL. Nonsense mutations in the OCRL-1 gene in patients with the oculocerebrorenal syndrome of Lowe. Hum Mol Genet 1993; 2: 461-463.
175. Prié D, Huart V, Bakouh N et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002; 347: 983-991.
176. Bergwitz C, Roslin NM, Tieder M et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006; 78: 179-192.
177. Schubert C. The genomic basis of the Williams-Beuren syndrome. Cell Mol Life Sci 2009; 66: 1178-1197.
178. Weber S, Schneider L, Peters M et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2001; 12: 1872-1881.
179. Konrad M, Schaller A, Seelow D et al. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 2006; 79: 949-957.
180. Font-Llitjó s M, Jiménez-Vidal M, Bisceglia L et al. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J Med Genet 2005; 42: 58-68.
181. Wilson JM, Young AB, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. N Engl J Med 2010; 309: 900-910.
182. Cochat P, Pichault V, Bacchetta J et al. Nephrolithiasis related to inborn metabolic diseases. Pediatr Nephrol 2010; 25: 415-424.
183. Takeuchi H, Kaneko Y, Fujita J et al. A case of a compound heterozygote for adenine phosphoribosyltransferase deficiency (APRT*J/APRT*Q0) leading to 2,8-dihydroxyadenine urolithiasis: review of the reported cases with 2,8-dihydroxyadenine stones in Japan. J Urol 1993; 149: 824-826.
184. Wakida N, Tuyen DG, Adachi M et al. Mutations in human urate transporter 1 gene in presecretory reabsorption defect type of familial renal hypouricemia. J Clin Endocrinol Metab 2005; 90: 2169-2174.
185. Fry AC, Karet FE. Inherited renal acidoses. Physiology (Bethesda) 2007; 22: 202-211.
186. Chadha V, Alon US. Hereditary renal tubular disorders. Semin Nephrol 2009; 29: 399-411.